echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA: Real-time continuous blood glucose monitoring can improve glycosylated hemoglobin and reduce the rate of hypoglycemia in patients with DM receiving insulin treatment

    JAMA: Real-time continuous blood glucose monitoring can improve glycosylated hemoglobin and reduce the rate of hypoglycemia in patients with DM receiving insulin treatment

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Continuous blood glucose monitoring (CGM) is recommended for type 1 diabetic patients; CGM for insulin-treated type 2 diabetic patients lacks observational evidence
    .
    In diabetic patients receiving insulin therapy, is there any clinical benefit in real-time continuous blood glucose monitoring (CGM)? Andrew J.


    Karte et al.


    Diabetes evaluated the clinical results of real-time CGM .


    The study was an exploratory retrospective cohort study of the changes in results related to the initiation of real-time CGM, using variance analysis to estimate


    .


    A total of 41,753 insulin-treated diabetic patients (5673 cases of type 1 DM; 36 080 cases of type 2 DM) received treatment from the Northern California Comprehensive Medical Service System (2014-2019), received insulin therapy, and self-monitored blood glucose levels.
    Use CGM


    .


    Measure 10 endpoints 12 months before baseline and 12 months after baseline: HbA1c; hypoglycemia (for emergency or hospital use); hyperglycemia (for emergency department or hospital use); HbA1c levels below 7%, below 8%, More than 9%; 1 or more visits to the emergency department for any reason; 1 or more hospitalizations for any reason; number of outpatient visits and phone calls
    .

    Hypoglycemia

    The real-time CGM initiation group included 3806 patients (mean age 42.
    4 years [SD, 19.


    9 years]; 51% women; 91% type 1 and 9% type 2); the non-CGM group included 37947 patients (mean age 63.


    The rate of hypoglycemia in the real-time CGM group decreased from 5.


    Compared with patients who did not use DM, patients with diabetes who received insulin therapy who underwent real-time continuous blood glucose monitoring had a significant improvement in glycosylated hemoglobin, and fewer people went to emergency and hospitalization due to hypoglycemia


    Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R.


    Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.


    Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R.
    Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    JAMA.
    2021;325(22):2273-2284 .
    doi:10.
    1001/jama.
    2021.
    6530 Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R.
    Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    JAMA.
    Here leave a message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.